Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma

Research output: Contribution to journalArticlepeer-review


Classical Hodgkin's lymphoma accounts for approximately 10% of all malignant lymphomas. Although most patients can be cured with modern treatment strategies, approximately 25% of them experience either primary or secondary chemorefractoriness or disease relapse, thus requiring novel treatments. Increasing preclinical and clinical evidences have demonstrated the role of microenvironment in the molecular pathogenesis of classical Hodgkin's lymphoma and elucidated the complex cross-talk between the malignant Hodgkin Reed-Sternberg cells and the nonmalignant, reactive cells of the microenvironment, strongly supporting novel therapeutic approaches aimed at targeting Hodgkin's Reed-Sternberg cells along with reactive cells in order to overcome chemorefractoriness. In the near future, these novel therapies will also be tested in chemosensitive patients to reduce long-term toxicities of chemo-radiotherapy.

Original languageEnglish
Pages (from-to)807-817
Number of pages11
JournalBiomarkers in Medicine
Issue number8
Publication statusPublished - Aug 1 2015


  • brentuximab vedotin
  • CD30
  • classical Hodgkin's lymphoma
  • Hodgkin Reed-Sternberg cells
  • nivolumab
  • PD-1 ligands
  • PD-1 receptor
  • relapsed/refractory Hodgkin's lymphoma
  • targeted therapy
  • tumor microenvironment

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery


Dive into the research topics of 'Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this